THERACLION (ISIN: FR0010120402; Mnemo: ALTHE), an innovative company developing Sonovein®, a robotic platform for ...

LONDON, June 7, 2017 /PRNewswire/ -- High-Intensity Focused Ultrasound (HIFU) is an FDA-approved, minimally invasive therapeutic technology with the potential to transform the treatment of many ...

Focal One Robotic HIFU Patient Story Featured on Health Uncensored with Dr. Drew on Lifetime Network ...

LYON, France, January 31, 2022 -- EDAP TMS SA (EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced positive clinical results from the Endo-HIFU-R1 Phase 2 study ...

LYON, France, October 1, 2024 - EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, today announced that the first patients have been treated in a Phase I/II study ...

In 2015, Houston Methodist Hospital made the decision to invest in a medical technology that had not yet been approved by the US Food & Drug Administration. The procedure, called High Intensity ...

LYON, France,January 29, 2020 – EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced that the University of Miami Sylvester Comprehensive ...

DUBLIN, Aug. 3, 2023 /PRNewswire/ -- The "Global High Intensity Focused Ultrasound (HIFU) Therapy Market, Company Profiles, Product Analysis & Recent Development - Forecast to 2030" report has been ...

Record full-year 2024 HIFU revenue of USD 25.7 million, an increase of 15.3% over full-year 2023 Record Q4 2024 HIFU revenue of USD 9.3 million, an increase of 15.0% over Q4 2023 U.S. Focal One HIFU ...

LYON, France, November 30, 2022-- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic therapeutic ultrasound, today announced that the Company has received approval from French ...